Keytruda beaten by Summit’s bispecific in NSCLC
The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.
Where Will Merck Stock Be in 5 Years?
Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...
clinicaltrialsarena15d
Summit’s checkpoint inhibitor trumps Keytruda in lung cancer trial
Summit shared data from the HARMONi-2 study at the World Conference on Lung Cancer (WCLC) conference in San Diego.
The Pharma Letter6d
First FDA nod for Keytruda in MPM
Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
(OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose ...
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
The Pharma Letter8d
ESMO 2024: Merck & Co keeps Keytruda data coming
As ever, US pharma giant Merck & Co has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda ...
AstraZeneca and MSD hail progress in tackling hard-to-treat cancers
Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...
AOL11d
Where Will Merck Stock Be in 5 Years?
On the other hand, investors must assess some uncertainty regarding the Keytruda platform, which could lose its patent exclusivity by the end of this decade, forcing Merck to find a new growth driver.